

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
18 November 2004 (18.11.2004)

PCT

(10) International Publication Number
WO 2004/098579 A2

(51) International Patent Classification⁷: A61K 31/00 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/GB2004/001926

(22) International Filing Date: 4 May 2004 (04.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0310881.8 12 May 2003 (12.05.2003) GB

(71) Applicant (for all designated States except US): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon Hertfordshire EN11 9BU (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): CASTRO PINEIRO, Jose, Luis [ES/GB]; Terlings Park, Eastwick Road, Harlow Essex CM20 2QR (GB).

(74) Agent: HORGAN, James, Michael, Frederic; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).

Published:
— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/098579 A2

(54) Title: COMBINATION OF A GLYCINE/NMDA ANTAGONIST AND A TACHYKININ NK-1 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF NEURODEGENERATION

(57) Abstract: The present invention relates to a pharmaceutical formulation comprising a compound which is active as an antagonist of the strychnine-insensitive glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor in combination with a tachykinin NK-1 receptor antagonist, for use in the treatment of neurodegeneration arising, in particular, from stroke or cerebral ischemia.